恩威医药
(301331)
| 流通市值：33.58亿 | | | 总市值：33.65亿 |
| 流通股本：1.03亿 | | | 总股本：1.03亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 636,853,560 | 449,221,452.75 | 196,499,491.35 | 812,127,431.13 |
| 营业收入 | 636,853,560 | 449,221,452.75 | 196,499,491.35 | 812,127,431.13 |
| 二、营业总成本 | 603,849,773.06 | 408,252,811.68 | 183,733,734.69 | 763,172,474.47 |
| 营业成本 | 329,741,094.37 | 228,665,720.71 | 101,928,907.9 | 399,443,939.66 |
| 税金及附加 | 7,706,635.08 | 5,351,510.43 | 2,056,668.59 | 12,555,058.15 |
| 销售费用 | 210,066,218.18 | 136,750,988.16 | 60,842,025.31 | 267,145,001.09 |
| 管理费用 | 51,950,007.37 | 34,640,236.72 | 17,722,947.71 | 76,226,203.19 |
| 研发费用 | 4,302,882.29 | 2,538,865.32 | 1,085,549.14 | 9,073,915.83 |
| 财务费用 | 82,935.77 | 305,490.34 | 97,636.04 | -1,271,643.45 |
| 其中:利息费用 | 2,252,232.68 | 1,645,288.24 | 828,750 | 2,426,424.62 |
| 其中:利息收入 | 2,319,824.36 | 1,448,947.99 | 791,658.07 | 4,090,693.9 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 4,140,865.67 | 2,818,800.74 | 1,132,468.42 | 3,494,421.27 |
| 资产处置收益 | -263,274.66 | -263,274.66 | - | -263,488.07 |
| 资产减值损失(新) | 3,109,451.04 | 1,948,506.26 | 2,643,099.55 | -3,877,937 |
| 信用减值损失(新) | 1,043,729.5 | -1,278,804.58 | 601,274.29 | -1,506,376.82 |
| 其他收益 | 2,322,109.27 | 1,707,535.87 | 1,053,346.16 | 2,884,939.95 |
| 四、营业利润 | 43,356,667.76 | 45,901,404.7 | 18,195,945.08 | 49,686,515.99 |
| 加:营业外收入 | 53,413.64 | 41,133.13 | 1,506.8 | 223,998.78 |
| 减:营业外支出 | 222,519.93 | 213,098.44 | 210,812.14 | 3,226,680.45 |
| 五、利润总额 | 43,187,561.47 | 45,729,439.39 | 17,986,639.74 | 46,683,834.32 |
| 减:所得税费用 | 6,602,899.8 | 7,385,258.14 | 1,681,512.85 | 9,186,289.97 |
| 六、净利润 | 36,584,661.67 | 38,344,181.25 | 16,305,126.89 | 37,497,544.35 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 36,584,661.67 | 38,344,181.25 | 16,305,126.89 | 37,497,544.35 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 36,584,661.67 | 38,344,181.25 | 16,305,126.89 | 37,497,544.35 |
| 扣除非经常损益后的净利润 | 31,871,915.37 | 35,275,716.98 | 14,624,801.81 | 34,729,637.24 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.37 | 0.38 | 0.16 | 0.37 |
| (二)稀释每股收益 | 0.37 | 0.38 | 0.16 | 0.37 |
| 九、综合收益总额 | 36,584,661.67 | 38,344,181.25 | 16,305,126.89 | 37,497,544.35 |
| 归属于母公司股东的综合收益总额 | 36,584,661.67 | 38,344,181.25 | 16,305,126.89 | 37,497,544.35 |
| 公告日期 | 2025-10-30 | 2025-08-26 | 2025-04-21 | 2025-04-21 |
| 审计意见(境内) | | | | 标准无保留意见 |